Cencora, Inc 8-K, filed Nov 4, 2021
Cencora, Inc. (COR)
8-K
2021-11-04
For: 2021-11-04
View Original
Added on
April 10, 2026
About this 8-K
Cencora, Inc filed this 8-K on November 4, 2021.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
_________________________________
FORM 8-K
_________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 4, 2021
_________________________________
(Exact name of registrant as specified in its charter)
_________________________________
Commission File Number: 1-6671
| (State or other jurisdiction of | (I.R.S. Employer | |||||||||||||
| incorporation or organization) | Identification No.) | |||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||||||||
(610 ) 727-7000
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | |||||||||
| (NYSE) | |||||||||||
_________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 7.01. Regulation FD Disclosure.
Recently, AmerisourceBergen Corporation (the "Company") undertook a strategic evaluation of its reporting structure to reflect its expanded international presence as a result of the June 2021 acquisition of Alliance Healthcare. As a result of this review, beginning in the first quarter of fiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions. U.S. Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services reportable segment (excluding Profarma Distribuidora de Produtos Farmacêuticos S.A. ("Profarma")), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty. Profarma had previously been included in the Pharmaceutical Distribution Services reportable segment. Profarma Specialty had previously been reported in Other. Beginning in the first quarter of fiscal 2022, the Company will report its results under this new structure.
In the attached Exhibit 99.1, which is incorporated herein by reference, the Company is voluntarily furnishing a supplemental disclosure of unaudited revised reportable segment information for each of the quarters of fiscal 2021 and the fiscal year ended September 30, 2021 under the reporting structure that is expected to be utilized in fiscal 2022 to assist investors in analyzing the changes to its reporting structure.
The information contained in this Current Report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number | Description of Exhibit | |||||||
| 99.1 | ||||||||
| 104 | Cover Page Interactive Data File (formatted as inline XBRL) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AMERISOURCEBERGEN CORPORATION | |||||||||||
| Date: | November 4, 2021 | By: | /s/ James F. Cleary | ||||||||
| Name: | James F. Cleary | ||||||||||
| Title: | Executive Vice President & Chief Financial Officer | ||||||||||
Exhibit 99.1
AMERISOURCEBERGEN CORPORATION
SUMMARY SEGMENT INFORMATION
(in thousands)
(unaudited)
The following illustrates revised reportable segment revenue for the periods indicated:
| Fiscal Year Ended September 30, 2021 | ||||||||||||||||||||||||||||||||
| Revenue | First Quarter | Second Quarter | Third Quarter | Fourth Quarter | Fiscal Year | |||||||||||||||||||||||||||
| (As Revised) | (As Revised) | (As Revised) | (As Revised) | (As Revised) | ||||||||||||||||||||||||||||
| U.S. Healthcare Solutions | $ | 51,572,581 | $ | 48,165,587 | $ | 50,375,842 | $ | 52,347,535 | $ | 202,461,545 | ||||||||||||||||||||||
| International Healthcare Solutions | 944,311 | 989,032 | 3,030,769 | 6,565,517 | 11,529,629 | |||||||||||||||||||||||||||
| Intersegment eliminations | (336) | (448) | (916) | (631) | (2,331) | |||||||||||||||||||||||||||
| Revenue | $ | 52,516,556 | $ | 49,154,171 | $ | 53,405,695 | $ | 58,912,421 | $ | 213,988,843 | ||||||||||||||||||||||
The following illustrates revised reportable segment operating income for the periods indicated:
| Fiscal Year Ended September 30, 2021 | ||||||||||||||||||||||||||||||||
| Segment Operating Income | First Quarter | Second Quarter | Third Quarter | Fourth Quarter | Fiscal Year | |||||||||||||||||||||||||||
| (As Revised) | (As Revised) | (As Revised) | (As Revised) | (As Revised) | ||||||||||||||||||||||||||||
| U.S. Healthcare Solutions | $ | 565,927 | $ | 654,715 | $ | 529,790 | $ | 507,486 | $ | 2,257,918 | ||||||||||||||||||||||
| International Healthcare Solutions | 50,989 | 51,843 | 100,831 | 186,623 | 390,286 | |||||||||||||||||||||||||||
| Total segment operating income | $ | 616,916 | $ | 706,558 | $ | 630,621 | $ | 694,109 | $ | 2,648,204 | ||||||||||||||||||||||
The following reconciles total segment operating income to income before income taxes for the periods indicated:
| Fiscal Year Ended September 30, 2021 | ||||||||||||||||||||||||||||||||
| (in thousands) | First Quarter | Second Quarter | Third Quarter | Fourth Quarter | Fiscal Year | |||||||||||||||||||||||||||
| Total segment operating income | $ | 616,916 | $ | 706,558 | $ | 630,621 | $ | 694,109 | $ | 2,648,204 | ||||||||||||||||||||||
| Gains from antitrust litigation settlements | — | — | 147,432 | 21,362 | 168,794 | |||||||||||||||||||||||||||
| LIFO credit | 25,727 | 20,918 | 113,920 | 42,463 | 203,028 | |||||||||||||||||||||||||||
| Acquisition-related intangibles amortization | (25,034) | (24,973) | (44,282) | (81,932) | (176,221) | |||||||||||||||||||||||||||
| Employee severance, litigation, and other | (70,381) | (78,156) | (226,964) | (96,410) | (471,911) | |||||||||||||||||||||||||||
| Goodwill impairment | — | — | — | (6,373) | (6,373) | |||||||||||||||||||||||||||
| Impairment of assets | — | — | — | (11,324) | (11,324) | |||||||||||||||||||||||||||
| Operating income | 547,228 | 624,347 | 620,727 | 561,895 | 2,354,197 | |||||||||||||||||||||||||||
| Other (income) loss | (14,268) | 23,310 | (4,141) | (46,637) | (41,736) | |||||||||||||||||||||||||||
| Interest expense, net | 33,614 | 34,526 | 51,338 | 54,596 | 174,074 | |||||||||||||||||||||||||||
| Income before income taxes | $ | 527,882 | $ | 566,511 | $ | 573,530 | $ | 553,936 | $ | 2,221,859 | ||||||||||||||||||||||